The sodium glucose cotransporter 2 (SGLT2) reabsorbs most of the glucose filtered by the kidneys. SGLT2 inhibitors reduce glucose reabsorption, thereby lowering blood glucose levels, and have been approved as new antihyperglycemic drugs. Although the therapeutic strategy is very promising, many questions remain.
INTRODUCTION
Diabetes mellitus is a growing health concern worldwide [1] . Normalizing hyperglycemia is vital in slowing the progression of the disease process and preventing the devastating secondary consequences including cardiovascular disease and nephropathy. Inhibitors of sodium glucose cotransporter 2 (SGLT2) have recently been approved as new antihyperglycemic drugs in type 2 diabetes mellitus (T2DM). Studies are underway in type 1 diabetes mellitus (T1DM) using SGLT2 inhibitors as an add-on to insulin therapy. These compounds inhibit the reabsorption of glucose in the kidney, a process that is enhanced in diabetes, thereby spilling glucose into the urine and lowering blood glucose levels (Figs 1 and 2 ). In contrast to many of the current antidiabetic therapies, SGLT2 inhibitors can lower body weight, work independent of endogenous insulin, and have little risk of hypoglycemia (see [2] [3] [4] [5] for review).
Although this new class of antidiabetic compounds is very promising, many questions remain.
In this review, we will discuss new insights on the biology of SGLT2 and the consequences of SGLT2 inhibition on the kidney and beyond.
160-180 g of glucose is filtered each day and nearly completely reabsorbed by the kidneys. The sodium glucose transporters SGLT2 and SGLT1 in the luminal membrane of the proximal tubule have been established as the primary mechanisms of glucose reabsorption in the kidney [4] [5] [6] (Fig. 2 ). Using validated antibodies and knockout mice as negative controls, the SGLT2 protein has been localized in the luminal membrane of the early proximal tubule (S1 and S2 segments), whereas the SGLT1 protein is expressed in the late proximal tubule (S3 segment) in rodents [7, 8] . Recent studies using well validated antibodies confirmed this expression pattern in the human kidney, and found that, in contrast to rodents, renal SGLT2 expression was sex-independent [9 & ]. Studies in knockout mice demonstrated that SGLT2 is responsible for all glucose reabsorption in the early proximal tubule and for most kidney glucose reabsorption overall [7] , whereas SGLT1 reabsorbs 3% of the filtered glucose in euglycemia [10] . Net renal glucose reabsorption is absent during pharmacologic SGLT2 inhibition in SGLT1À/À mice, as well as in SGLT1/SGLT2 double knockout mice [11 & ], indicating that SGLT2 and SGLT1 can explain all renal glucose reabsorption in euglycemia and that SGLT2 reabsorbs $97% in euglycemia.
DIABETES INCREASES RENAL SODIUM GLUCOSE COTRANSPORTER 2 EXPRESSION AND GLUCOSE REABSORPTION
In T1DM and T2DM, the kidneys increase their glucose transport maximum by $20% to 600 gram/day. This could be secondary to proximal tubular growth and an increase in SGLT2 expression; however, no data using primary tissue samples and validated antibodies are available in humans, and previous studies in rodents provided conflicting results [5, 12] . Using knockout mice as critical negative antibody controls, renal protein expression of SGLT2 was shown to be increased by 40 Other studies indicated that renal SGLT1 protein expression is suppressed whenever the late proximal tubule is exposed to high glucose levels, as observed in normoglycemic SGLT2À/À mice [7] , as well as in nondiabetic mice given a SGLT2 inhibitor or in T1DM Akita mice [14 & ]. Despite this downregulation, overall glucose transport through SGLT1 was greatly increased in those settings because of the increased glucose load to the late proximal tubule [7,11 & ] ( Fig. 2 ). We speculated that downregulation of SGLT1 is a protective mechanism to attenuate glucotoxicity in the vulnerable S3 segments within the outer medulla [4] . Upregulation of SGLT2 and downregulation of SGLT1 in diabetes are both expected to enhance the glucosuric and thereby the blood glucose lowering effect of SGLT2 inhibition.
MOLECULAR REGULATION OF SODIUM GLUCOSE COTRANSPORTER 2 EXPRESSION AND ACTIVITY
Studies in mice have shown that pharmacological SGLT2 inhibition itself also increases renal SGLT2 protein expression, that is, under conditions when the physiologic uptake of glucose into the early proximal tubule is inhibited [14 & ]. The mechanisms involved in SGLT2 upregulation under these conditions and in response to diabetes (see above) remain poorly understood. Studies in human embryonic kidney (HEK-293 T) cells indicated that insulin phosphorylates SGLT2 on Ser624, thereby increasing its activity [16] . Studies in cultured human proximal tubular cells reported that insulin, but not high glucose, enhanced SGLT2 protein expression. The insulin-induced increase in SGLT2 expression was associated with an increased reactive oxygen species content and attenuated by N-acetylcysteine [17] . Insulin binding in the kidney corresponds to sites of SGLT2 expression, and therefore the insulin release following ingestion of a glucoserich meal may activate SGLT2 to retain the ingested glucose in the body [18] . Although hyperinsulinemia may contribute to the increased SGLT2 protein expression and activity in T2DM db/db mice, it KEY POINTS SGLT2 inhibition on pancreatic alfa cells increases glucagon release which can help prevent/attenuate hypoglycemia.
SGLT2 inhibitors induce a multitude of effects that have the potential to affect the progression of the primary diabetic disease as well as its cardiovascular consequences, with little risk for hypoglycemia. SGLT2 inhibition has the potential for nephroprotection through blood glucose-dependent and independent effects.
There is a need to better understand the effects of SGLT2 inhibitors on renal outer medulla, PCKD, ketoacidosis, NHE3, uric acid excretion, and renal gluconeogenesis. & ]. Other molecules implicated in the upregulation of SGLT2 activity include protein kinase C and protein kinase A, whereas angiotensin II AT1 receptors and hepatocyte nuclear factor HNF-1a have been proposed to increase SGLT2 expression in the diabetic state (for review see [12, 19] ). More studies are needed to better understand the nuances of the regulation of SGLT2 expression and activity.
Is there relevant extrarenal expression of SGLT2? This question is important for the clinical use of SGLT2 inhibitors, and, consistent with previous reports in humans and mice [4] , a recent study could not detect SGLT2 mRNA in human small intestine, liver, heart, lung, fat tissue, and brain [9 & ]. Obviously, negative results cannot exclude small amounts of SGLT2 mRNA expression, and, as discussed below, new studies indicated that SGLT2 is expressed and functionally active in glucagon-secreting alfa cells of the pancreatic islets [20 && ].
WHY DO SODIUM GLUCOSE COTRANSPORTER 2 INHIBITORS ONLY EXCRETE 50-60% OF THE FILTERED GLUCOSE?
If SGLT2 reabsorbs $97% of filtered glucose, then it is surprising that humans treated with SGLT2 inhibitors only excrete 50-60% of the filtered glucose [4] . This is mimicked in SGLT2 knockout mice, in which mean fractional glucose excretion was 64% [7] . Studies in SGLT1À/À mice have indicated that SGLT2 inhibition strongly increases SGLT1-mediated glucose reabsorption [21] , and demonstrated that the increase in SGLT1-mediated glucose reabsorption fully explained the fractional glucose reabsorption of 40-50% during SGLT2 inhibition in euglycemic mice 
SODIUM GLUCOSE COTRANSPORTER 2 INHIBITION AND HYPOGLYCEMIA, GLUCONEOGENESIS, b CELL PRESERVATION, AND KETOGENESIS
According to a meta-analysis of patients with T2DM, SGLT2 inhibitors decreased HbA1C levels by 0.5-0.7% at 12 weeks of treatment, and this effect persisted for up to 52 weeks. Hypoglycemia was noted only when SGLT2 inhibitors were used in combination with other drugs, but not as monotherapy [23] . The blood glucose lowering effects of SGLT2 inhibition depended on both serum glucose concentration and GFR. These two parameters determine how much glucose is delivered to SGLT2 in the early proximal tubule, and thus how much glucose can be excreted by SGLT2 inhibition. Therefore, lower values for each parameter are associated with lesser blood glucose lowering. Currently, SGLT2 inhibitors are approved for use only in type 2 diabetes, with dapagliflozin approved for GFR > 60 ml/min and canagliflozin and empagliflozin for GFR > 45 ml/min. Notably, SGLT2 inhibition in T2DM patients with stage 3 chronic kidney disease (CKD) (estimated GFR between 30 and 60 ml/min) was still able to reduce HbA1C by 0.42% at 24 weeks [24] . SGLT2 inhibitors lower blood glucose, and to some extent GFR (see below), and thereby their glucosuric potential, which is expected to help prevent and/or attenuate episodes of hypoglycemia. Gluconeogenesis is another important mechanism that serves to maintain normal blood glucose levels and prevent hypoglycemia. As expected for blood glucose lowering agents, SGLT2 inhibition increased plasma glucagon concentrations and endogenous glucose production in T2DM db/db mice [25] , diabetic TALLYHO/JngJ mice [25] , insulin-resistant mice [20 && ], and in patients with T2DM [26, 27] . Importantly, evidence was provided that SGLT2 itself is expressed on glucagon-secreting alfa cells in the pancreas, the expression is reduced in diabetic patients, and inhibition of SGLT2 on pancreatic alfa cells can induce glucagon release [20 && ]. Thus, SGLT2 inhibition can induce glucagon release and, as a consequence, hepatic gluconeogenesis by lowering blood glucose levels, as well as direct effects on alfa cells ( Fig. 1 ).
Although the central role of the liver in gluconeogenesis is well established and recognized, the kidneys also produce between 15-55 g glucose/day, and this process is upregulated in diabetes [28] . Phosphoenolpyruvate carboxykinase (PEPCK) is the main regulator of gluconeogenesis and is upregulated in the kidneys of diabetic rats and humans. Studies in T1DM Akita mice confirmed that renal PEPCK mRNA was upregulated; however, this effect was attenuated by SGLT2 inhibition [14 & ]. Thus, SGLT2 inhibition may lower blood glucose levels in diabetes by inhibiting renal glucose reabsorption and renal gluconeogenesis ( Fig. 1) . In contrast to the liver, little is known about the regulation of gluconeogenesis in the kidney, and further studies are needed in this regard to further define the involved mechanisms and quantitative potential of SGLT2 inhibition.
Previous studies have shown that SGLT2 inhibition improved insulin sensitivity and increased Sodium glucose cotransporter 2 and the kidney Novikov and Vallon b-cell mass in moderately hyperglycemic female Zucker diabetic fatty rats, that is, in an early-stage T2DM model [29] . Using male Zucker diabetic fatty rats, it was shown that SGLT2 inhibitors also evoked b-cell sparing effects in progressed T2DM with features of reduced b-cell mass [30 && ]. Thus, SGLT2 inhibition, possibly by lowering glucose toxicity, may slow the loss of b cells in T2DM, and thereby the progression of the disease (Fig. 1) .
In May 2015, the US Food and Drug Administration released a warning that SGLT2 inhibitors might increase the risk of ketoacidosis (http:// www.fda.gov/Drugs/DrugSafety/ucm446845.htm). Cases have been reported in both T1DM and T2DM diabetic patients. Potential mechanisms include lower insulin and higher glucagon levels in response to SGLT2 inhibition which can lead to increased lipolysis and ketogenesis, and potentially increased renal tubular reabsorption of ketones [31] (Fig. 1) . The recently reported EMPA-REG OUTCOME study (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients; see more details below) found no difference in rates of ketoacidosis in patients with T2DM treated with the SGLT2 inhibitor empagliflozin versus placebo over the course of 3 years [32 && ]. Nevertheless, dedicated studies are needed to further define the clinical relevance and the involved mechanisms.
SODIUM GLUCOSE COTRANSPORTER 2 INHIBITION REDUCES HYPERTENSION, BODY WEIGHT, AND CARDIOVASCULAR MORTALITY IN TYPE 2 DIABETES MELLITUS
Hypertension and obesity are important cardiovascular risk factors. Consistent with preclinical data, a meta-analysis of T2DM patients treated with SGLT2 inhibitors showed a consistent small decrease in SBP of between 3-6 mmHg [23] . This effect is likely because of a direct natriuretic and osmotic effect and body weight reduction by SGLT2 inhibition (Fig. 1) . Recent studies provided evidence that SGLT2 and NHE3 may be functionally linked such that SGLT2 inhibition may also inhibit the Na/H exchanger NHE3 in the proximal tubule [33 && ,34 & ] (Fig. 2) . Although such an interaction could be relevant for the effects of SGLT2 inhibition on GFR and blood pressure, more studies are required to further establish this interaction and its cardiovascular relevance. SGLT2 inhibition may also induce beneficial cardiovascular effects by lowering plasma uric acid levels. Although the involved transport mechanism and relevance remains to be determined, there is evidence that glycosuria rather than hyperglycemia increases uricosuria in T1DM patients [35] .
In both animal studies and human trials in T2DM, the glucosuric effect of SGLT2 inhibition was consistently associated with lower body weight. In obese rats and mice, the reduction in body weight in response to SGLT2 inhibition was associated with lower body fat and increased lipolysis and fatty acid oxidation [36, 37] . Lesser visceral and subcutaneous fat has been reported in T2DM patients treated with SGLT2 inhibitors [38, 39] (Fig. 1) . In contrast to T2DM, lipolysis is increased and body fat and body weight are often reduced in poorly controlled T1DM. Notably, SGLT2 inhibition improved blood glucose in T1DM Akita mice, and this was associated with increased body weight and epididymal fat adipocyte size [14 & ], indicating that the effect of SGLT2 inhibition on body fat may be affected by the underlining pathophysiology.
The EMPA-REG OUTCOME trial compared the treatment of the SGLT2 inhibitor empagliflozin versus placebo for 3 years in addition to standard care in 7020 patients with T2DM and high cardiovascular risk [32 && ]. Empagliflozin was associated with small improvements in blood glucose control and small reductions in weight, waist circumference, uric acid level, and SBP and DBP, with no increase in heart rate, and small increases in both low-density lipoprotein and high-density lipoprotein cholesterol. Importantly, empagliflozin treatment reduced the risk of death from cardiovascular disease, hospitalization for heart failure, and death from any cause (relative risk reductions of 38, 35, and 32%, respectively) [32 && ].
DOES SODIUM GLUCOSE COTRANSPORTER 2 INHIBITION PROVIDE KIDNEY PROTECTION BEYOND LOWERING BLOOD GLUCOSE LEVELS?
Diabetes is a leading cause of CKD and end stage renal disease. SGLT2 inhibition may induce beneficial effects on the reno-cardiovascular system by lowering blood glucose, body weight, and blood pressure (see above). The pathophysiology of diabetic kidney disease is still poorly understood. T1DM and T2DM can lead to early kidney growth, glomerular hyperfiltration, and proinflammatory processes which have been associated with a greater risk for later nephropathy [12] . Beneficial effects on these parameters may have nephroprotective potential, and SGLT2 inhibition could affect these parameters through lowering blood glucose levels or because the kidneys sense hyperglycemia and glucotoxicity in part through SGLT2-mediated glucose uptake. To address this issue requires considering the metabolism, needs, and complexity of the in-vivo renal system.
Sodium glucose cotransporter 2 inhibition lowers hyperfiltration independent of lowering blood glucose
Hyperglycemia increases the glucose delivery to the proximal tubule and is associated with tubular growth. According to the tubular hypothesis of glomerular hyperfiltration in the diabetic kidney (for review see [12] ), these changes increase proximal tubular reabsorption of glucose and Na via SGLT2 and SGLT1, of Na via Na/H exchanger NHE3, and secondarily of Cl, K and fluid; this in turn reduces the tubular Na, Cl, K, and fluid load to the macula densa and distal tubule; to restore the NaCl and fluid load to the early distal tubule, the GFR is increased through the physiology of tubuloglomerular feedback as well as the reduction in Bowman space hydrostatic pressure, which is a determinant of the filtration pressure and is sensitive to distal tubular fluid load (Fig. 2) . The quantitative role of glucose reabsorption in diabetic glomerular hyperfiltration and mechanistic insights have been demonstrated in rats by local application into the early proximal tubule of a nonselective SGLT inhibitor [40] and by systemic application of a selective SGLT2 inhibitor [41] , as well as by studies in diabetic SGLT2 knockout mice [13 & ]. All these maneuvers lowered GFR, and the GFR effect did not require a lowering of blood glucose levels, but was associated with an increased NaCl concentration at the macula densa [40, 41] and an increase in the hydrostatic pressure in Bowman space [40] (Figs 1  and 2 ). In accordance, SGLT2 inhibition for 15 weeks prevented glomerular hyperfiltration in T1DM Akita mice [14 & ]. Recent studies confirmed such an effect in humans. In an 8-week study of T1DM patients, SGLT2 inhibition decreased GFR by 19% in patients with baseline hyperfiltration; again, this effect was independent of blood glucose lowering [42 && ]. SGLT2 inhibition for 3 weeks also induced a small reduction in estimated GFR and in albumin to creatinine ratios in T2DM patients with a baseline GFR of 30-50 ml/ min; these effects were mostly maintained over 26 weeks [43] . Similar effects were observed for up to 52 weeks of therapy in T2DM patients with CKD stage 2-3 [24] . Assuming that CKD is associated with deleterious glomerular hyperfiltration in the remaining intact nephrons, and therefore a high glucose delivery to the individual early proximal tubule, the reduction in GFR in response to SGLT2 inhibition is expected under these conditions in accordance with the tubular hypothesis [4] (Fig. 2 ).
Sodium glucose cotransporter 2 inhibition may lower early kidney growth and inflammation by lowering blood glucose SGLT2 gene knockout decreased blood glucose levels from 470 to 300 mg/dl in streptozotocin-induced T1DM mice, but did not attenuate the increase in kidney weight, markers of kidney growth, and inflammation or injury observed over a period of 4.5 months [13 & ]. SGLT2 inhibition in T1DM Akita mice lowered blood glucose from 500 to 200 mg/dl; at such a strong blood glucose effect (see paper for explanations), SGLT2 inhibition attenuated kidney growth, glomerular growth, molecular markers of renal growth, albuminuria, and inflammation, apparently in proportion to blood glucose levels [14 & ]. SGLT2 inhibition also reduced blood glucose from 400 to 200 mg/dl in T2DM ob/ob mice; again this was associated with a decrease in renal hypertrophy, albuminuria, and markers of inflammation and mesangial matrix expansion [15 & ]. Furthermore, in T1DM endothelial nitric oxide synthase knockout mice with matched high blood glucose levels across all groups, those with SGLT2 inhibition showed no benefit on glomerulosclerosis, tubular atrophy, or tubulointerstitial fibrosis, whereas those treated with an angiotensin II AT1 receptor antagonist did [44 & ].
Together, these studies are consistent with the notion that SGLT2 inhibition can lower early growth and inflammation in the diabetic kidney primarily by lowering blood glucose (Fig. 1) .
WHAT IS THE CONSEQUENCE OF INCREASING GLUCOSE DELIVERY TO THE SEGMENTS DOWNSTREAM OF THE EARLY PROXIMAL TUBULE BY SODIUM GLUCOSE COTRANSPORTER 2 INHIBITION?
The main side-effect of SGLT2 inhibition is an increased risk of genital infections and, to a relatively lesser extent, urinary tract infections ( Fig. 1 ). There is some remaining discussion on the precise role of glucosuria as a causative factor for these infections [45] . Importantly, upper urinary tract infection (pyelonephritis) is not increased by SGLT2 inhibitors. Humans with familial renal glycosuria because of mutations in SGLT2 do not show signs of general renal tubular dysfunction or other pathological changes; in accordance, genetic or pharmacologic inhibition of SGLT2 in nondiabetic rodents induced glucosuria with no changes in kidney injury markers, or only minor increases in markers of tubular growth and protective mechanisms, respectively [4, 5] .
Using mathematical modeling of the rat proximal tubule, it was proposed that SGLT2 inhibition reduced proximal tubular Na reabsorption, but increased oxygen consumption in the outer medullary S3 segment by increasing Na and glucose delivery to this segment, and inhibiting passive paracellular reabsorption, and thereby increasing active transcellular reabsorption [46 & ]. The model further predicted that diabetes increased proximal tubular oxygen consumption mostly as a consequence of glomerular hyperfiltration and increased tubular work load. Therefore, the net effect of SGLT2 inhibition on proximal tubular Na reabsorption and oxygen consumption was proposed to largely depend on the extent of the GFRlowering effect [46 & ]. Along these lines, acute nonselective SGLT inhibition improved cortical oxygen tension in streptozotocin-induced T1DM rats, whereas it reduced medullary oxygen tension in control and diabetic rats [47 & ]. These modeling and experimental data indicate that SGLT2 inhibition may enhance medullary hypoxia by inhibiting paracellular reabsorption in the S3 segment and redistribution of Na reabsorption to the S3 segment and medullary thick ascending limb, whereas such an effect is counteracted by the reduction in blood glucose and GFR (Figs 1 and 2) . Longer-term experimental studies and studies in humans are needed, as well as studies that address the question of whether conditions that increase renal medullary hypoxia (e.g., ischemia-reperfusion or nephrotoxins) increase the sensitivity to SGLT2 inhibition. In this regard, the EMPA-REG OUTCOME trial found that the proportions of patients with adverse events, including acute renal failure, were similar in patients treated with SGLT2 inhibitor versus placebo. In a subgroup analysis of patients with GFR < 60 ml/min (CKD3), there was a favorable, although not statistically significant, trend toward the primary cardiovascular outcome in the empagliflozin treatment group [32 && ]. Studies using a rat model of polycystic kidney disease (PCKD) found that SGLT2 inhibition for 6 weeks increased cyst volume and induced a 23% higher total kidney weight, without reducing creatinine clearance or changing renal cyclic adenosine monophosphate content or increasing staining for Ki67 as a marker of cell proliferation [48 & ]. This could be of relevance if prescribing SGLT2 inhibitors to PCKD patients. Further dedicated experimental and clinical studies, and careful evaluation of ongoing longer-term clinical studies, will help to refine our understanding of the renal pharmacodynamics and safety of SGLT2 inhibitors (Fig. 1 ).
EFFECTS OF SODIUM GLUCOSE COTRANSPORTER 2 INHIBITION BEYOND THE RENO-CARDIOVASCULAR SYSTEM
SGLT2 inhibition is a chronic therapy and its effects on other clinical conditions are of great interest. In this regard, it was reported that glycemic control by SGLT2 inhibition for 10 weeks ameliorated cognitive dysfunction in obese T2DM mice [49] . Moreover, SGLT2 expression was detected in human pancreatic and prostate adenocarcinomas, and SGLT2 inhibitors blocked glucose uptake and reduced tumor growth and survival in a xenograft model of pancreatic cancer. Thus, imaging of functional SGLT2 by PET may help to diagnose and stage pancreatic and prostate cancers, and SGLT2 inhibitors may serve for cancer therapy [50 & ].
CONCLUSION SGLT2 inhibitors induce a multitude of effects in the diabetic setting that have the potential to affect the progression of the primary disease as well as its cardiovascular consequences, including beneficial effects on blood glucose, body weight, body fat, pancreatic b cells, glomerular hyperfiltration, kidney growth and inflammation, and hypertension, associated with little risk for hypoglycemia. New studies provided further mechanistic clues, but also indicated the need to better understand the nuances of SGLT2 inhibition, including effects on the outer medulla, in PCKD as well as their potential for ketoacidosis. In addition to EMPA-REG OUTCOME, there are several studies underway looking at the effects of SGLT2 [3] ). Their results will come out in the next few years, complement the results from EMPA-REG OUTCOME, and help to further refine our understanding of the therapeutic potential and safety of SGLT2 inhibition. The study showed that genetic models of T1DM and T2DM have increased renal SGLT2 expression. SGLT2 knockout lowers the diabetesinduced glomerular hyperfiltration independent of lowering blood glucose levels. SGLT2 inhibition in the absence of a strong effect on hyperglycemia is not sufficient to attenuate early kidney growth and inflammation in diabetes.
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